CStone and IMPACT Therapeutics’ clinical collaboration progresses to IND filing acceptance for CS1001+IMP4297 combination therapy
SUZHOU, China, Feb. 8, 2019 /PRNewswire/ — CStone Pharmaceutical (“CStone”) and IMPACT Therapeutics, Inc. (“IMPACT”) today jointly announced that an Investigational New Drug (IND) filing has been accepted by the…